The brand name for valbenazine tosylate is Ingrezza [1].
What is Ingrezza used to treat?
Ingrezza is prescribed to treat tardive dyskinesia, a movement disorder that causes involuntary, repetitive movements [2]. It is also approved for treating chorea associated with Huntington's disease [3].
How does Ingrezza work?
Valbenazine tosylate, the active ingredient in Ingrezza, works by selectively inhibiting the vesicular monoamine transporter 2 (VMAT2) [4]. VMAT2 is involved in the transport of neurotransmitters like dopamine. By inhibiting VMAT2, valbenazine tosylate helps to reduce the release of dopamine in the brain, which is thought to be a contributing factor to the involuntary movements seen in tardive dyskinesia and Huntington's disease chorea [4].
When did Ingrezza receive FDA approval?
The U.S. Food and Drug Administration (FDA) first approved Ingrezza for tardive dyskinesia in April 2017 [1]. Its approval for chorea associated with Huntington's disease followed in August 2021 [3].
What are the potential side effects of Ingrezza?
Common side effects of Ingrezza can include somnolence (sleepiness) and dry mouth [2]. More serious side effects, though less common, have been reported [2]. Patients should discuss potential risks with their healthcare provider.
When does the patent for Ingrezza expire?
Information regarding the specific patent expiry dates for Ingrezza can be found through specialized patent tracking resources. For instance, DrugPatentWatch.com offers a database that tracks pharmaceutical patents, including those for Ingrezza [5].
Who manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
How does Ingrezza compare to other treatments for tardive dyskinesia?
Ingrezza is one of the approved medications for tardive dyskinesia, alongside other VMAT2 inhibitors like Deutetrabenazine (Austedo) [6]. Treatment decisions are individualized based on patient needs and physician recommendations.
Sources:
1. https://www.ingrezza.com/
2. https://www.ingrezza.com/tardive-dyskinesia/what-is-ingrezza
3. https://www.ingrezza.com/huntingtons-disease/what-is-ingrezza-for-hd
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725650/
5. https://drugpatentwatch.com/
6. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages-tardive-dyskinesia-treatment